Stockreport

Esperion: Early Commercial Success Supports A Buy At These Prices [Seeking Alpha]

Esperion Therapeutics, Inc.  (ESPR) 
Last esperion therapeutics, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.esperion.com
PDF SummaryEsperion's NEXLETOL and NEXLIZET are affordable, convenient, oral, once-daily, non-statin, LDL-C medicines recently approved by the FDA and European Commission. I [Read more]